Key Takeaway: The article discusses the exploratory outcomes of the Phase 2 SHINE trial assessing CT1812 in Alzheimer's patients. Results were presented at the 2024 Alzheimer's Association International Conference in Philadelphia. The findings focus on CSF proteomics biomarkers, which may provide insights into the treatment's effects on Alzheimer's disease.
Price reaction · baseline $2.37 (2024-07-26 close) · hit pre-market · 1 other CGTX headline(s) in the window, move may be shared
day 0 close
-43.9%
day 1
-53.6%
day 3 · peak
-62%
Market Sentiment Analysis
POSITIVE FACTORS
The study presents exploratory outcomes that may enhance understanding of Alzheimer's.
CT1812 shows potential as a therapeutic option for Alzheimer's patients.
The presentation at a prestigious conference highlights the significance of the findings.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
DiCaro V, Lizama BN, Cho E, et al. Exploratory CSF Proteomics Biomarker Outcomes of The Phase 2 Clinical Trial SHINE to Assess The Effects of CT1812 in Alzheimer’s Patients . Poster presented at 2024 Alzheimer’s Association International Conference (AAIC) ; Philadelphia, PA.
Frequently Asked Questions
What was the focus of the SHINE trial?
The SHINE trial focused on assessing the effects of CT1812 in Alzheimer's patients.
Where were the findings of the trial presented?
The findings were presented at the 2024 Alzheimer's Association International Conference.
What type of biomarkers were explored in the trial?
The trial explored exploratory CSF proteomics biomarkers.
What is the significance of CT1812?
CT1812 is being evaluated as a potential therapeutic option for Alzheimer's disease.